Brought to you by 
Hoechst, Vertex expand ICE alliance
Apr 2000
Executive Summary
Hoechst has obtained an exclusive worldwide license from Vertex (small molecule drugs) to develop, manufacture, and market Phase I HMR 3480/VX-740 as a therapy for rheumatoid arthritis and an exclusive option for all other compounds discovered under a previous agreement.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R+D and Marketing-Licensing
- Co-Promotion
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Hoechst, Vertex expand ICE alliance
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice